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Abstract  
INTRODUCTION: Distal renal tubular acidosis (dRTA) is associated with renal stone 
disease and it often needs to be considered and excluded in some recurrent calcium 
kidney stone formers (KSF). However, a diagnosis of dRTA, especially when 
‘incomplete’, can be missed and needs to be confirmed by a urinary acidification test. 
The ‘gold standard’ reference test is still the short ammonium chloride (NH4Cl) test, 
but it is limited by gastrointestinal side effects and occasionally failure to ingest 
sufficient NH4Cl. For this reason, the furosemide plus fludrocortisone (F+F) test has 
been proposed as an easier and better-tolerated screening test. The aim of the present 
study was to assess the usefulness of the F+F test as a clinical screening tool for 
dRTA in a renal stone clinic. 
METHODS: We studied 124 patients retrospectively in whom incomplete dRTA was 
suspected: 71 had kidney stones only, 9 had nephrocalcinosis only, and 44 had both. 
A total of 158 urinary acidification tests were performed: 124 F+F and 34 NH4Cl; 
both tests were completed in 34 patients. 
RESULTS: Mean age was 45.4 ± 15 years and 49% of patients were male.  The 
prevalence of complete and incomplete dRTA was 7% and 13.7 %, respectively. Of 
34 patients tested using both tests, 17 (50%) were abnormal and 4 (12%) were normal. 
Thirteen (39%) patients were abnormal by F+F, but normal by NH4Cl (sensitivity 
100% [95% CI 80% to 100%], specificity 24% [95% CI 7% to 50%]; positive 
predictive value 57% [95% CI 37% to 75%], negative predictive value 100% [95% CI 
40% to 100%]). 
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CONCLUSIONS: The F+F test is characterised by an excellent sensitivity and 
negative predictive value, and the diagnosis of incomplete dRTA can be excluded 
reliably in a patient who acidifies their urine normally with this test. However, its lack 
of specificity is a drawback, and if there is any doubt, an abnormal F+F test may need 
to be confirmed by a follow-up NH4Cl test. Ideally, a prospective blinded study in 
unselected KSF is needed to accurately assess the reliability of the F+F test in 
diagnosing, rather than excluding, dRTA. 
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Introduction  
Urinary pH is an important factor in determining the risk of forming particular types 
of kidney stone: an acid pH favours uric acid, mixed uric acid and oxalate, and cystine 
stones; an alkaline pH favours calcium phosphate stones. The latter stone type, 
especially when almost 100%, can suggest a defect in urinary acidification (UA) and 
an underlying diagnosis of renal tubular acidosis (RTA). (1). Since an alkaline pH 
favors calcium phosphate precipitation, especially when there is also increased 
urinary calcium excretion and hypocitraturia, normal UA helps prevent calcium 
phosphate stone formation. (2-4) 
One of the commonest causes of abnormal UA is RTA, most commonly in its classic 
type I or distal form (dRTA), which is characterized by a hyperchloremic, normal 
anion gap metabolic acidosis, with reduced net acid excretion, and inability to lower 
urine pH below 5.3. The clinical features of dRTA can range from an asymptomatic 
UA defect without systemic acidosis (so-called 'incomplete' dRTA), but with stones 
or radiological nephrocalcinosis, to major signs and symptoms in childhood due to 
metabolic acidosis causing growth retardation and rickets, and extensive medullary 
nephrocalcinosis with stones, leading rarely to renal failure (5). 
Several studies have reported a high prevalence of dRTA in recurrent KSF; moreover, 
incomplete dRTA has been shown to be associated with a more clinically severe form 
of stone disease characterised by early onset, multiple recurrences, and increased need 
for surgery (6-9). In patients with a metabolic acidosis and near-normal glomerular 
filtration rate, a diagnosis of dRTA can be made when urine pH is consistently >5.3, 
but if there is no systemic acidosis, a test of urinary acidification is required.  
In 1959, Wrong and Davies (10) described the short ammonium chloride (NH4Cl) 
test, which involved the oral ingestion of ammonium chloride to generate an acid load 
 5 
to lower systemic pH, and has been adopted as the 'gold standard' diagnostic test for 
dRTA. However, this test suffers from the drawback of frequent gastric irritation, 
with nausea and sometimes vomiting, from the ingested acid load. Subsequently, 
several authors described the use of oral furosemide to augment distal nephron 
sodium delivery and increase the lumen-negative electrical gradient favoring 
increased proton (H+) secretion (11-14). This effect has been shown to be enhanced 
by concomitant administration of fludrocortisone, which stimulates the sodium pump 
and increases epithelial sodium channel-mediated sodium reabsorption in principal 
cells, as well as directly stimulating H+ pump activity in α-intercalated cells (5,14). 
In 2007, we described the ‘F+F test’, in which the administration of furosemide and 
with fludrocortisone was shown to provide a sufficient and more consistent stimulus 
to acid excretion than furosemide alone in healthy subjects, and in patients known to 
have dRTA (5). In that study, we evaluated 11 control subjects and 10 patients with 
known dRTA by giving oral NH4Cl or F+F in random order, and we found that the 
simultaneous administration of furosemide and fludrocortisone provided an easy, 
effective, and well-tolerated alternative to the standard short NH4Cl test described by 
Wrong and Davies (10). Since our report, we have continued to use the F+F test in 
our routine clinical practice to screen patients with suspected dRTA, and we have 
studied many patients with recurrent calcium nephrolithiasis. The aim of the present 
study is to report our experience to date in using the F+F test in a large cohort of 
selected recurrent calcium KSF, and to compare the F+F and NH4Cl test findings. 
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Methods  
Study population  
This is a retrospective study that evaluated adult patients attending the metabolic 
stone metabolic of the Royal Free Hospital, London. Patients who completed 
simultaneous F+F and/or NH4Cl tests, and had a confirmed diagnosis of recurrent 
calcium kidney stone disease and/or nephrocalcinosis were investigated. All patients 
had one of the following clinical criteria suggestive of underlying dRTA: repeated 
clinic dipsticks urine pH of 6 or greater, relatively low (normal) 24-h urinary citrate 
excretion, or a predominantly calcium phosphate stone in the absence of infection.  
Most patients included in this study had normal kidney function, with mean serum 
creatinine concentrations of 100 ± 61.6 µmol/L in the whole group. However, 17 
patients had CKD IIIa and IIIb (creatinine ranged between 125 to 267µmol/L), and 
one patient had CKD V (creatinine 586µmol/L). 
Patients without nephrolithiasis or nephrocalcinosis or non-calcium kidney stone 
disease (uric acid stones, cystine stones, infection-related stones, also primary 
hyperoxaluria, and known dRTA or drug-related stones) were excluded from the 
analysis.  
 
Study variables 
Demographic and clinical characteristics were collected retrospectively by reviewing 
the patient’s computerized records and included age, sex, duration of stone disease, 
family history of kidney stones, and history of urinary tract infections. Patients 
underwent a fasting blood sample for the determination of urea, creatinine, 
electrolytes, calcium (total and corrected for serum albumin), bicarbonate, and a 24-h 
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urine collection for measurement of urinary pH (u.pH), citrate (u.Cit), and creatinine 
excretions. For patients that spontaneously passed stones or that underwent surgery 
for kidney stones, biochemical stone analysis was performed.  
 
F+F and NH4Cl tests 
All patients underwent a simultaneous F+F test. Patients with a normal test result 
(trough pH <5.3) were considered not have dRTA. All patients with an abnormal F+F 
test (a failed test: trough pH>5.3) went on to have a short NH4Cl test (Figure 1). This 
was done to confirm the diagnosis of dRTA and to evaluate the reliability of the F+F 
test in detecting dRTA compared with the reference NH4Cl test. Tests were performed 
on separate days, without fasting, and with at least 1 week between tests.  
The F+F test involved taking a baseline urine sample, followed by oral administration 
of furosemide (40 mg) and fludrocortisone (1 mg). Fluid intake was ad libitum. Urine 
was collected hourly for 6 h after the baseline sample. 
The NH4Cl test involved taking a baseline urine sample, followed by oral NH4Cl at a 
dose of 100 mg/kg body weight given as 500 mg gelatine capsules. This dose was 
taken over 1 h with water to minimize gastric irritation. Urine was then collected 
every hour, starting 2 h after dosing began, until 8 h after the baseline sample. 
Patients were instructed to note the time at which they had passed urine before the 
baseline urine sample to allow baseline values to be determined. Urine pH was 
measured immediately with an electrode pH meter (Hannah piccoloTM).  
University College London Hospital Ethics Committee had approved the test 
protocols. Written consent was not obtained for reporting this study from the 
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anonymised individual patients, because the study was based on data collected as part 
of routine clinical care. 
Statistical analysis was by Student's t-test for unpaired data or by analysis of variance 
followed by Student's t-test for paired data, as appropriate. Nominal and categorical 
variables were compared using the chi-square likelihood ratio or Fisher's exact test. 
Values are given as means SD; P<0.05 was taken to denote a significant difference. 
Sensitivity, specificity and predictive values of F+F test were also calculated. 
 
Definitions of complete dRTA and incomplete dRTA 
Complete distal RTA was diagnosed if a patient had metabolic acidosis, urine pH >6 
and abnormal F+F and/or NH4Cl test.  A patient was diagnosed with incomplete 
dRTA if he or she had either an abnormal F+F or NH4Cl test. In patients who had 
both tests, a diagnosis of dRTA was made if both tests were abnormal in the case of 
concordant results; in the case of a disagreement between the tests, the diagnosis of 
dRTA was based on the results of NH4Cl test, which was considered to be the ‘gold 
standard’ reference test. 
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Results  
During the period from 2007 to 2013 a total of 217 UA tests were performed in a 
cohort of 169 patients. Thirty-six patients (52 urinary acidification tests) were 
excluded as they had a diagnosis other than recurrent kidney stones and/or 
nephrocalcinosis. Nine patients were excluded as they had only NH4Cl tests done (in 
two of them the test was not completed). 
The remaining 124 patients suffered from recurrent kidney stones and/or had 
nephrocalcinosis, and were included in the analysis. Of these 124 patients, 71 had 
only kidney stones, 9 had only nephrocalcinosis, and 44 had both. A total of 158 
urinary acidification tests were performed: 124 F+F and 34 NH4Cl tests. Thirty-four 
patients had both tests. One patient had two F+F tests.  
The demographic and clinical characteristics of the study patients are shown in Table 
1. Mean age was 45.4 ± 15 years and 49% of the patients were male.  The majority of 
KSF (99 patients, 79%) had stones in both kidneys and the remainder had unilateral 
disease. Nine patients (7.2%) had staghorn calculi, and two were diagnosed with 
medullary sponge kidney (MSK). Fifteen patients had a history of recurrent UTIs and 
11 had a positive family history of kidney stones. Eighteen patients had a diagnosis of 
an autoimmune disorder; seven of these had Sjogren’s syndrome.  
Data on stone composition were available in 77 of the 124 patients (62%). More than 
60% of samples were stones composed of more than one constituent. The prevalence 
of calcium phosphate stones was 35% (44 patients).  
Table 2 shows laboratory characteristics of the study patients and prevalence of 
biochemical blood and urinary abnormalities. The majority of patients had normal 
serum potassium, calcium, bicarbonate, and creatinine levels. The prevalence of 
hypokalemia, hyperkalemia, hyperchloremia, and metabolic acidosis was 2.4, 4, 15 
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and 7%, respectively. Baseline urine pH > 6 and hypocitraturia were detected in 55 
and 27% of the patients, respectively.  
 
Prevalence of complete and incomplete dRTA as detected by F+F and/or NH4Cl 
tests 
Of 158 tests, 67 tests (42%) were abnormal (an inability to acidify urine below pH 
5.3) and 91 were normal. 
Demographic, clinical and laboratory characteristics of 50 patients with abnormal F+F 
test and/or NH4Cl were compared with 74 patients who had normal tests (Table 3). 
Patients with abnormal UA tests were significantly younger and, as expected, had a 
higher prevalence of nephrocalcinosis, lower serum potassium and bicarbonate levels, 
higher serum creatinine, lower urinary citrate, and more alkaline urine. There were no 
statistically significant differences in prevalence of bilateral kidney stones, 
autoimmune disease, recurrent UTIs, hyperchloremia or serum calcium level. 
To assess the ability of the F+F test in detecting dRTA as compared with the NH4Cl 
test, patients tested by using both tests were analyzed.   Overall, 34 patients were 
tested by both methods, of which 17 (50%) were abnormal and 4 (12%) were normal 
by both methods. The remaining 13 (39%) patients were abnormal by F+F test, but 
normal by NH4Cl test. Thus, the F+F test had a sensitivity of 100% (95% CI 80% to 
100%), a specificity of 24% (95% CI 7% to 50%), a positive predictive value of 57% 
(95% CI 37% to 75%), and a negative predictive value of 100% (95% CI 40% to 
100%). No demographic or clinical variables that predicted false positivity of the F+F 
test could be detected. 
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In Table 4 (see supplementary data) we have summarized the demographic, clinical 
and laboratory characteristics of patients stratified into 8 subgroups according to their 
results (normal or abnormal) of either NH4Cl or F+F test as follow: NH4Cl only – 
normal; NH4Cl only – abnormal; F+F only – normal; F+F only – abnormal; NH4Cl 
abnormal, F+F abnormal (no patients); NH4Cl abnormal, F+F normal; NH4Cl 
normal, F+F abnormal; NH4Cl normal , F+F normal (Table 4, supplementary data). 
Urinary acidification was more rapid after the F+F test than after NH4Cl test, as noted 
previously. All patients acidified their urine to pH<5.3 by 3–4 h after the F+F test, 
whereas this occurred 4–5 h after the ingestion of NH4Cl. 
To access the ability of clinical parameters as hypocitraturia and alkaline urine to 
diagnose dRTA and probably substitute F+F test, we analyzed sensitivity and 
specificity of combination of 24 hour u. citrate < 1.52mmol/day and u. ph > 6 as 
compared with F+F test. We found sensitivity of 52% (CI 0.36-0.68); specificity 86% 
(CI 0.74-0.93), positive predictive value 71%, and negative predictive value 74%. 
Although high specificity of these combinations provides the ability of the test to 
correctly identify those patients without dRTA, a low sensitivity led to a high rate of 
false negative results. 
However, because the F+F test has high sensitivity/low specificity, and hypocitraturia 
and alkaline urine have low sensitivity/high specificity, a suitable alternative is to 
subject patients initially to a F+F test with high sensitivity, and then evaluate urinary 
pH and citrate that have high specificity. In this way, nearly all the false positives 
reported by the F+F test may be correctly identified if 24 hour urinary citrate 
excretion and urine pH are also taken into account. That is if a patient has an 
abnormal F+F test, and 24 hour urinary citrate excretion is < 1.52 mmol/day and urine 
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pH > 6, a diagnosis of dRTA is very likely, and confirmation by a follow-up NH4Cl 
test may not be required. 
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Discussion  
Our study evaluated the prevalence of distal urinary acidification (UA) defects in a 
selected cohort of patients with recurrent KSF or nephrocalcinosis using the 
simultaneous F+F test, and has addressed its efficacy and reliability compared with 
the well-established short NH4Cl test. Distal UA defects were common in our 
patients: up to 14% had incomplete, and an additional 7% had complete, dRTA. This 
finding can be explained by the clinical characteristics of our patients in whom a high 
prevalence of severe bilateral kidney stone disease, nephrocalcinosis, alkaline urine, 
and calcium phosphate stone type all suggested the possibility of a UA abnormality. 
As expected, lower serum potassium and bicarbonate, hypocitraturia and more 
alkaline urine were associated with incomplete dRTA. Interestingly, these patients 
had higher serum creatinine levels, suggesting more clinically severe stone disease 
that had resulted in some renal impairment, possibly due to complications of 
obstruction, infection, and the need for repeated surgical interventions. 
Several previous studies have addressed the prevalence and clinical significance of 
dRTA in KSF and found that 19 -31% of recurrent KSF suffer from UA defects (6-9); 
indeed, an even higher prevalence was detected in patients with bilateral and severe 
stone disease. On the other hand, dRTA was less prevalent (6.7%) in a recent 
retrospective analysis of 150 consecutive male idiopathic recurrent calcium stone 
formers in which the NH4Cl test was carried out in only 12 patients with a baseline 
urinary pH 5.8 or greater (15). In this study, incomplete dRTA was found in 1 in 15 
male KSF, while in our more selective study it is in 1 in 8 patients. This difference 
can be explained by the differences in the populations studied, since incomplete 
dRTA is more common in female stone formers and is found more often in patients 
with bilateral stone disease (8,9). Moreover, selection of patients on the basis of 
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urinary pH alone can be misleading, for example, in the presence of infection or other 
cause of increased ammonium content; but can also result in underestimation of 
acidification defects, since a small proportion of our patients with incomplete dRTA 
(4%) had baseline urinary pH values of less than 5.8 (ranged 5.6 – 5.71). Regardless 
of these discrepancies, our results confirm that distal nephron acidification defects are 
common in patients with severe forms of calcium stone disease and/or 
nephrocalcinosis, and a defect in UA should be sought in all recurrent KSF, especially 
given the possibility of more targeted therapeutic and prophylactic interventions (16). 
Of importance, most of our patients had incomplete acidification defects that can be 
unmasked only if UA tests are performed. 
The more novel aspect of our study is the assessment of the F+F test compared with 
the short NH4Cl test in KSF. We found that the F+F test has high sensitivity and 
negative predictive value. Thus, the diagnosis of dRTA can be reliably excluded in 
patients who acidify urine normally with the F+F test. However, the test’s lack of 
specificity in these circumstances is an important limitation, because an abnormal test 
may need to be confirmed by a follow-up NH4Cl test. However, we could not identify 
any demographic or clinical variables that predict the likelihood of a falsely abnormal 
F+F test. 
Approximately 10% of our patients suffered from CKD III. The impact of CKD on 
urinary pH and the potential effect of reduced GFR on performance of both 
ammonium chloride and F+F test are important (10). Metabolic acidosis is a frequent 
finding in CKD and is due to reduced excretion of ammonium, the major and adaptive 
buffer for renal acid excretion (and bicarbonate synthesis), with a preserved ability to 
lower urinary pH (17). The defective molecular pathways in metabolic acidosis in 
CKD have been investigated recently in an experimental study by Bürki and co-
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workers (18). They found a significant decrease in the abundance and activity of key 
enzymes and transporters for proximal tubular ammoniagenesis (phosphate-dependent 
glutaminase, PEPCK and SNAT3) and bicarbonate transport (NBCe1) in animals with 
CKD compared with controls. However, final ammonium excretion and urinary 
acidification also depend on distal nephron function (19):  the two rhesus proteins 
RhBG and RhCG mediate distal secretion of ammonia/ammonium, although the 
driving force for ammonia/ammonium secretion depends on the degree of urinary 
acidification by Type A intercalated cells. In the study of Bürki and colleagues, 
urinary pH was more acidic in CKD rats under baseline conditions and was acidified 
further on an HCl diet, demonstrating an intact capacity to generate and maintain a 
steep proton gradient from the interstitium to the collecting duct lumen (18). AE1 
mRNA expression and protein abundance were decreased in CKD animals, whereas 
the B1H+-ATPase subunit was unaffected. Although the capacity of the collecting 
duct to maximally acidify urine might be affected, excretion of a more acidic urine, 
and ability to reduce further urine pH with an acid load seems to be preserved in 
CKD, as reported originally by Wrong & Davies (10). Therefore, it seems likely that 
the results of UA testing should still be reliable in patients with CKD. 
The present study confirms our previous finding that the simultaneous F+F test takes 
less time to complete, with any differences between normal and impaired UA evident 
by 3–4 h from the start of the test; whereas with the NH4Cl test takes 4-5 h, and urine 
pH can remain low for up to 8 h.  Thus, the convenience, low side-effect profile and 
shorter duration (lasting a maximum of 4 h with hourly urine pH measurements being 
made starting immediately before dosing) of the F+F test are useful advantages for a 
more routine screening tool to exclude a possible diagnosis of dRTA. 
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However, our study found a high incidence of false positives for incomplete dRTA 
with the F+F test when compared with NH4Cl test. Although the reason for this is not 
completely clear, we suspect that the different physiological mechanisms of urine 
acidification underlying these two tests may explain the inconsistency.  Direct NH4Cl 
loading has an effect on systemic acid-base and plasma pH, and is a powerful 
stimulus to urine acidification. In contrast, the F+F test works essentially by 
increasing distal tubular delivery of sodium to the collecting duct principal cells and 
stimulates sodium reabsorption with its effect on the transepithelial voltage favoring 
intercalated cell H+ secretion, both effects primed by co-administration of 
fludrocortisone; however, this may still prove to be a less potent and consistent 
stimulus to acid excretion and may therefore ‘over-diagnose’ an acidification defect. 
A similar problem can occur with NH4Cl loading, if the full oral dose is not taken or 
tolerated because of nausea and vomiting - the main limitation of this test - in addition 
to the time it takes to complete.  
Viljoen et al. have used both F+F and NH4Cl tests in 10 adult patients with clinical 
suspicion of dRTA and recurrent nephrolithiasis and 10 healthy volunteers (20). 
While 10 patients acidified urine normally with NH4Cl, with F+F only 3 of 10 
reduced their urine pH to <5.3. Thus, similar to our study, the negative predictive 
value of the F+F for disease was 100%, but the positive predictive value was low, 
which, despite this, we still believe makes the modified F+F test a more convenient 
screening tool for a mixed population of KSFs. An important additional finding of our 
study is that the combination of abnormal F+F test with hypocitraturia and an alkaline 
urine increases its ability to correctly diagnose dRTA, and may avoid an NH4Cl test. 
Our study has limitations. First, demographic and clinical variables were collected 
retrospectively by reviewing patients’ computerized records and we cannot exclude 
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all potential confounding factors. However, data collection was uniform in all patients 
and the same research physicians have completed all datasheets. Second, our patients 
represent a selected subgroup of KSF in whom a renal acidification defect was 
suspected on the basis of clinical characteristics. Thus, the high prevalence of 
incomplete dRTA cannot be extrapolated to lower risk and non-calcium KSF. A high 
pre-test probability of dRTA in our patients positively affects the predictive value of 
the F+F test and allows us to reach a scientifically reliable conclusion. Third, the 
incidence of side effects during either simultaneous F+F or NH4Cl tests was not 
recorded consistently. However, our previous study showed a high safety profile of 
the F+F test, whereas adverse gastrointestinal side effects are frequently reported with 
the NH4Cl test (10). Despite these limitations, we were able to demonstrate a high 
prevalence and clinical significance of distal urinary acidification defects in patients 
with recurrent and severe calcium KSF, and to provide evidence for the efficacy and 
reliability of simultaneous F+F testing in excluding dRTA.  
In summary, we evaluated a selected cohort of recurrent calcium KSF and focused 
specifically on the diagnosis of incomplete dRTA using the previously reported 
simultaneous F+F test. We found that this test has a high sensitivity, but low 
specificity, and it can reliably exclude a diagnosis of dRTA. However, in combination 
with clinical measures such as hypocitraturia and alkaline urine, which are routinely 
recorded in many KSF, the F+F test is reliable and can substitute for the NH4Cl test. 
This finding is important, because it can change the clinical approach to the patient 
and simplify the diagnosis of dRTA. 
Administration of alkali is a widespread therapy in almost all patients with idiopathic 
calcium stone disease, but the diagnosis of dRTA in its incomplete form has an 
important additional implication for bone health; moreover, giving a potassium salt is 
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also more beneficial, because of the associated potassium loss in dRTA, and therefore 
the dose may need to be higher, especially in younger RTA patients. Finally, the 
ability to diagnose dRTA promptly and conveniently does have implications for 
treatment and long-term management, especially in relation to growth in children and 
young adolescents, and bone health in adults (21,22). A future prospective 
randomized blinded study designed to compare the efficacy and reliability of 
simultaneous F+F with the short NH4Cl test in diagnosing dRTA in unselected 
recurrent calcium KSF would be an important and worthwhile next step. 
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Figure 1 Patient screening, enrollment and study flow 
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with suspected dRTA
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All patients underwent a simultaneous F+F test. Patients with normal test were 
considered not have dRTA. All patients with abnormal F+F test (test was considered 
abnormal (confirming a diagnosis of dRTA) if the urine pH did not fall to <5.3) went 
on to have a short NH4Cl test. This was done in order to confirm diagnosis of dRTA 
and to evaluate the ability of the F+F test in detecting dRTA as compared with the 
reference NH4Cl test. 
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Table 1. Demographic and clinical characteristics of the study patients 
 
All Patients N= 124 
Age, years 45.4 ± 15 
Male, n (%) 61 (49) 
Kidney Stone Disease  
Stones, n (%) 71 (57) 
Nephrocalcinosis, n (%) 9 (7.2) 
Stones and Nephrocalcinosis, n (%) 44 (35) 
Bilateral stones, n (%) 99 (79) 
Staghorn calculi, n (%) 9 (7.2) 
Recurrent UTI, n (%) 
 
15 (12) 
Positive family history of stone disease, n (%) 
 
11 (8.8) 
Sjogren syndrome, n (%) 
 
7 (5.6) 
Other autoimmune diseases, n (%)* 11 (8.8) 
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Sarcoidosis, n (%) 
  
2 (1.6) 
MSK, n (%) 
 
2 (1.6) 
Patients with known stone composition, n (%) 
 
77 (62) 
Calcium phosphate stones, n (%) 
 
44 (35) 
* 4 patients had SLE, 2 – necrotizing vasculitis, 1 – rheumatoid arthritis, 1 – 
myasthenia gravis, 2- autoimmune thyroiditis, 1- APLA. 
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Table 2. Laboratory characteristics of the study patients and prevalence of 
biochemical blood and urinary abnormalities 
 
All Patients N= 124 
Blood biochemistry  
Potassium, mmol/L 4.3 ± 0.47 
Calcium, mmol/L 2.33 ± 0.13 
Calcium corrected to albumin, mmol/L 2.32 ± 0.16 
Creatinine, µmol/L 98 ± 46 
Bicarbonate, mmol/L 26 ± 5.3 
Chloride, mmol/L 104 ± 8.5 
Hypokalemia, n (%) 3 (2.4) 
Hyperkalemia, n (%) 5 (4) 
Hyperchloremia, n (%) 25 (15) 
Metabolic acidosis, n (%) 9 (7) 
Urine biochemistry  
Creatinine, mmol/L 5.5 ± 4.2 
Creatinine, mmol /day 11.6 ± 4.2 
Baseline pH 6.3 ± 1.1 
 27 
Citrate, mmol /day 0.91 ± 0.7 
Baseline pH > 6, n% 70 (55) 
Hypocitraturia, n% 34 (27) 
 
Hyperchloremia was defined as serum chloride more than 106 mmol/L; Metabolic 
acidosis was defined as venous blood bicarbonate less than 22 mmol/L; Hypo- and 
hyperkalemia were defined as serum K less than 3.5 mmol/L or more than 5 mmol/L, 
respectively ; Hypocitraturia was defined as urine citrate excretion < 1.52 mmol/day. 
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Table 3. Demographic, clinical and laboratory characteristics of patients with 
abnormal F+F test and/or NH4Cl were compared to patients with normal tests 
Variables  Patients with abnormal 
F+F test and/or NH4Cl 
N=50 
Patients with 
normal  
F+F test and/or NH4Cl 
N=74 
p 
Age, years 41 ± 16 47.3 ± 13 0.05 
Male, n (%) 20 (40) 59 (79) 0.2 
Kidney Stone Disease    
Stones, n (%) 36 (72) 59 (78) 0.7 
Nephrocalcinosis, n (%) 26 (52) 16 (22) 0.006 
Bilateral stones, n (%) 34 (68) 50 (67) 0.8 
Recurrent UTI, n (%) 
 
10 (20) 5 (6.7) 0.5 
Positive family history of stone disease, n 
(%) 
 
5 (10) 6 (8) 0.5 
Autoimmune diseases, n (%)* 
 
9 (18) 9 (12) 0.4 
Calcium phosphate stones, n (%) 
 
16 (32) 26 (35) 0.9 
Blood biochemistry    
Potassium, mmol/L 4.2 ± 0.4 4.4 ± 0.47 0.001 
 29 
Calcium, mmol/L 2.3 ± 0.1 2.3 ± 0.1 0.2 
Calcium corrected to albumin, mmol/L 2.3 ± 0.15 2.3 ± 0.2 0.9 
Creatinine, µmol/L 121 ± 87 86 ± 21 0.02 
Bicarbonate, mmol/L 24.3 ± 3.5 27 ± 7.3 0.001 
Chloride, mmol/L 104 ± 3.5 104 ± 7.4 0.6 
Urine biochemistry    
Creatinine, mmol/L 4.3 ± 2.4 5.6 ± 3 0.02 
Creatinine, mmol /day 10.8 ± 3.9 12 ± 4.2 0.11 
Baseline pH 6.67 ± 0.4 6.1 ± 0.4 < 0.0001 
Citrate, mmol /day 1.4 ± 1 2.5 ± 1.4 < 0.0001 
Baseline pH > 6, n% 46 (92) 25 (33) 0.002 
 
* 7 patients had Sjogren Syndrome, 4 patients had SLE, 2 – necrotizing vasculitis, 1 – 
rheumatoid arthritis, 1 – myasthenia gravis, 2- autoimmune thyroiditis, 1- APLA. 
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Supplementary data 
Table 4. Demographic and laboratory characteristics of the patients stratified 
according to results (normal or abnormal) of either NH4Cl or F+F test as test as 
follow: NH4Cl only – normal; NH4Cl only – abnormal; F+F only – normal; F+F only 
– abnormal; NH4Cl abnormal, F+F abnormal (no patients); NH4Cl abnormal , F+F 
normal; NH4Cl normal , F+F abnormal; NH4Cl normal , F+F normal 
 NH4Cl 
Normal  
NH4Cl 
Abnormal  
F+F 
Normal 
F+F 
Abnormal 
NH4Cl 
abnormal/ 
F+F 
abnormal 
NH4Cl 
normal/ 
F+F 
abnormal 
NH4Cl 
normal/ 
F+F normal 
Patients N 17 17 91 33 17 13 4 
Age, years 46 ± 14 39 ± 16 48 ± 13 41 ± 16 39 ± 16 45 ± 18 47 ± 6 
Blood biochemistry        
Potassium, mmol/L 4.3 ± 0.4 4± 0.5 4.5 ± 0.4 4.2 ± 0.4 4± 0.5 4.3 ± 0.3 4.4 ± 0.4 
Calcium, mmol/L 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.09 2.3 ± 0.2 
Creatinine, µmol/L 80 ± 21 131 ± 82 89 ± 32 116 ± 88 131 ± 82 90 ± 46 78 ± 19 
Bicarbonate, mmol/L 26 ± 1.9 23 ± 3.5 26 ± 2.4 24 ± 3.5 23 ± 3.5 26 ± 2.6 25.7 ± 2.8 
Chloride, mmol/L 104 ± 2.1 104 ± 2.5 105 ± 7 104 ± 3.5 104 ± 2.5 105 ± 2.7 104 ± 1.2 
Urine biochemistry        
Baseline pH 6.3 ± 0.6 6.6 ± 0.6 6 ± 0.7 6.6 ± 0.3 6.6 ± 0.6 6.5 ± 0.5 6 ± 0.4 
Citrate, mmol /day 2.7 ± 1.5 1.3 ± 1.2 2.4 ± 1 2.4 ± 1.3 1.3 ± 1.2 3 ± 1.4 2.3 ± 0.4 
 
